Anti-Hypertensive Drugs - Zambia

Zambia

In Zambia, the revenue within the Anti-Hypertensive Drugs market is forecasted to attain a significant milestone, reaching US$2.97m in 2024.
It is anticipated that this revenue will demonstrate a steady annual growth rate (CAGR 2024-2029) of 0.86%, ultimately culminating in a market volume of US$3.10m by 2029.
When compared on a global scale, United States is projected to generate the highest revenue within this market, with an impressive figure of US$12,290.00m in the year 2024.
In Zambia, there is a growing demand for affordable generic anti-hypertensive drugs due to the high prevalence of hypertension and limited access to expensive branded medications.

Key regions: Japan, India, Italy, Brazil, South Korea

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Hypertensive Drugs market in Zambia is experiencing significant growth in recent years.

Customer preferences: Zambian customers are increasingly becoming aware of the importance of managing hypertension, leading to higher demand for anti-hypertensive drugs. Additionally, the country's aging population is also contributing to the growth of the market.

Trends in the market: There is a growing trend towards the use of combination therapies, which offer better efficacy and convenience for patients. This trend is also driven by the availability of more combination drugs in the market. Furthermore, the government's efforts to improve healthcare access and affordability are also contributing to the growth of the market.

Local special circumstances: Zambia is classified as a low-income country, with a significant proportion of the population living below the poverty line. This presents a challenge for the affordability of healthcare, including the cost of anti-hypertensive drugs. However, the government has implemented various initiatives to improve access to healthcare, including the provision of free healthcare for vulnerable groups.

Underlying macroeconomic factors: The Zambian economy has been growing in recent years, driven by the mining and agriculture sectors. This has led to an increase in disposable income and a growing middle class, which is contributing to the growth of the market. However, the country is also facing challenges such as high inflation and a high debt burden, which could impact the affordability of healthcare in the long term.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.